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ETATE-OF-THE-ART PAPER529Percutaneous Therapies for Mitral Regurgitationed Feldman, Mehmet Cilingiroglu
eldman and Cilingiroglu review the development of percutaneous therapies for mitral
egurgitation. Several techniques utilize the anatomy of the coronary sinus, which parallels
he posterior mitral leaflet to indirectly reshape the mitral annulus and reduce the degree of
itral regurgitation. Other techniques involve a retrograde approach and directly attempt to
lter the anatomy of the annulus. A third method attempts to reduce the amount of mitral
egurgitation via an edge-to-edge or double orifice repair, which involves clipping the
leaflets together. All 3 techniques are being actively developed, but none is ready yet for
idespread clinical use.CLINICAL RESEARCH NTERVENTIONAL CARDIOLOGY538Mixed Results for PCI Compared With CABG for ULM Stenosisnno Boudriot, Holger Thiele, Thomas Walther, Christoph Liebetrau, Peter Boeckstegers, Tilmann Pohl,
runo Reichart, Harald Mudra, Florian Beier, Brigitte Gansera, Franz-Josef Neumann, Michael Gick,
homas Zietak, Steffen Desch, Gerhard Schuler, Friedrich-Wilhelm Mohr
oudriot and colleagues compared sirolimus-eluting stenting to coronary artery bypass
rafting (CABG) for patients with unprotected left main (ULM) stenosis. The study
andomized 200 subjects who were deemed eligible for either approach. Percutaneous
oronary intervention (PCI) was inferior for the primary clinical end point, freedom from
ajor adverse cardiac events, which included target vessel revascularization within 12 months.
urther analyses showed that the combined rates for death and myocardial infarction were
omparable, but stenting resulted in more frequent repeat revascularization. These results
uggest that PCI may be as safe as CABG for ULM, but longer-term follow-up is needed.
ditorial Comment: Robert F. Wilson, Alan K. Berger, p. 546(continued on page A-22)
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iESYNCHRONIZATION THERAPY
549mpaired Renal Function Predicts
Echocardiographic Nonresponse and Poor Prognosis After CRTutger J. Van Bommel, Sjoerd A. Mollema, C. Jan Willem Borleffs, Matteo Bertini, Claudia Ypenburg,
ina Ajmone Marsan, Victoria Delgado, Ernst E. Van Der Wall, Martin J. Schalij, Jeroen J. Bax
an Bommel and colleagues investigated the effects of renal function on left ventricular (LV)
everse remodeling and long-term outcomes after cardiac resynchronization therapy (CRT).
early 500 subjects who underwent CRT were enrolled. Response to CRT was defined as a
ecrease in LV end-systolic volume 15% at 6-month follow-up. Responders had a higher
ean estimated glomerular filtration rate (eGFR) than nonresponders. During long-term
ollow-up, patients with an eGFR 60 ml/min/1.73 m2 had higher mortality than those with
igher eGFRs. Impaired renal function in CRT candidates is associated with nonresponse
nd worse clinical outcomes.EART RHYTHM DISORDERS556Incidence, Predictors, and Impact on Mortality of Inappropriate ICD Shocksohannes B. van Rees, C. Jan Willem Borleffs, Miha´ly K. de Bie, Theo Stijnen, Lieselot van Erven,
eroen J. Bax, Martin J. Schalij
an Rees and colleagues used a registry of over 1,500 subjects who received an implantable
ardioverter-defibrillator (ICD) to identify the incidence, predictors, and outcome of
nappropriate shocks. During a mean follow-up of 41 months, 13% of subjects experienced
or more inappropriate shocks. The cumulative incidence steadily increased to 18% at
-year follow-up. Independent predictors of inappropriate shocks included a history of atrial
brillation and age under 70 years. A single inappropriate shock resulted in an increased risk
or all-cause mortality; the risk was higher with more frequent inappropriate shocks. These
esults confirm that inappropriate ICD shocks are common and may increase the risk of
eath.EART RHYTHM DISORDERS563Prevention and Reversal of AF Inducibility by Vagosympathetic Nerve Stimulationia Sheng, Benjamin J. Scherlag, Lilei Yu, Shuyan Li, Reza Ali, Ying Zhang, Guosheng Fu,
iroshi Nakagawa, Warren M. Jackman, Ralph Lazzara, Sunny S. Po
heng and colleagues hypothesized that the autonomic atrial remodeling that accompanies
trial fibrillation (AF) could be reversed by low-level vagosympathetic nerve stimulation
LL-VNS). A series of experiments were completed in dogs. LL-VNS is electrical
timulation applied to both vagosympathetic trunks at voltages. This voltage is 10% to 50%
elow the threshold that slows sinus rate or atrioventricular conduction. LL-VNS reduced the
trial effective refractory period, the AF window of vulnerability, the AF duration, and the
F cycle length. These results show that LL-VNS can prevent and reverse atrial remodeling
nduced by rapid atrial pacing as well as suppress AF induced by cholinergic stimulation.(continued on page A-25)
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iYPERTROPHIC CARDIOMYOPATHY572Endocardial Radiofrequency Ablation for HOCMhorsten Lawrenz, Bianca Borchert, Christian Leuner, Markus Bartelsmeier, Jens Reinhardt,
laudia Strunk-Mueller, Dorothee Meyer Zu Vilsendorf, Marc Schloesser, Gerald Beer, Frank Lieder,
hristoph Stellbrink, Horst Kuhn
natomic variability of the vessels supplying the obstructing septal bulge can limit the efficacy
f transcoronary ablation of septal hypertrophy (TASH) for patients with hypertrophic
bstructive cardiomyopathy (HOCM). Lawrenz and colleagues hypothesized that endocardial
adiofrequency ablation of septal hypertrophy (ERASH) might be an alternative to TASH.
total of 19 patients with HOCM were enrolled; in 9 patients the left ventricular and in
0 patients the right ventricular septum was ablated. After a mean of 31 months, there was a
ignificant and sustained reduction in left ventricular outflow tract gradient, and there were
ignificant improvements in 6-min walking distance. ERASH appears to be a viable
herapeutic option in the treatment of HOCM and may be suitable for patients not amenable
or TASH or surgical myectomy.BESITY AND THE HEART577Obesity Induces Signs of Premature Cardiac Agingernd Niemann, Ying Chen, Mirja Teschner, Ling Li, Rolf-Edgar Silber, Susanne Rohrbach
iemann and colleagues investigated the influence of obesity on cardiac aging in patients
ndergoing cardiac surgery. Right atrial cardiomyocytes obtained from excised right atrial
ppendages were analyzed for mitochondrial function, markers of apoptosis, and oxidative
tress parameters. Obesity resulted in disturbed mitochondrial biogenesis and function and
as associated with signs of increased oxidative stress as well as telomere shortening. These
ata indicate that obesity results in premature cardiac aging, which may contribute to an
ncreased risk of heart failure.ditorial Comment: E. Dale Abel, p. 586ARDIOVASCULAR PHARMACOLOGY590Meta-Analysis Shows Limited Effect of Hydrochlorothiazide on 24-h Ambulatory BPranz H. Messerli, Harikrishna Makani, Alexandre Benjo, Jorge Romero, Carlos Alviar, Sripal Bangalore
ydrochlorothiazide (HCTZ) is the most commonly prescribed antihypertensive drug
orldwide; yet, the antihypertensive efficacy of HCTZ during 24 h of ambulatory blood
ressure (BP) monitoring is not clear. Messerli and colleagues performed a systematic review.
he decrease in 24-h BP with an HCTZ dose of 12.5 to 25 mg was systolic 6.5 mm Hg
nd diastolic 4.5 mm Hg, which was inferior compared with angiotensin-converting enzyme
nhibitors (mean BP reduction 12.9/7.7 mm Hg), angiotensin receptor blockers (13.3/7.8
m Hg), beta-blockers (11.2/8.5 mm Hg), and calcium antagonists (11.0/8.1 mm Hg). The
uthors further add that because outcomes data at this dose is lacking, HCTZ is an
nappropriate first-line drug for the treatment of hypertension.(continued on page A-32)
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aARDIOVASCULAR PHARMACOLOGY601Nebivolol Exerts Beneficial Effects Early After MI in a Mouse Modelajoscha A. Sorrentino, Carola Doerries, Costantina Manes, Thimoteus Speer, Chantal Dessy, Irina Lobysheva,
azma Mohmand, Razma Akbar, Ferdinand Bahlmann, Christian Besler, Arnd Schaefer,
enise Hilfiker-Kleiner, Thomas F. Lüscher, Jean-Luc Balligand, Helmut Drexler, Ulf Landmesser
ebivolol is a third-generation 1-adrenoreceptor antagonist that also stimulates endothelial
ell nitric oxide (NO) production and prevents vascular nicotinamide adenine dinucleotide
hosphate oxidase activation. Sorrentino and colleagues investigated whether nebivolol has
ffects on left ventricular (LV) dysfunction and remodeling early after myocardial infarction
MI) beyond its 1-receptor blocking properties. Mice with extensive anterior MI were
andomized to treatment with nebivolol, metoprolol-succinate, or placebo for 30 days after
I. Nebivolol improved endothelium-dependent vasorelaxation and increased the number of
arly endothelial progenitor cells. Nebivolol, but not metoprolol, improved LV dysfunction 4
eeks after MI and was associated with improved survival 4 weeks after MI. Nebivolol
mproves LV dysfunction and survival early after MI, likely beyond the effects provided by
onventional 1-receptor blockade.ARDIOVASCULAR PHARMACOLOGY612Pharmacogenetic Algorithm Best for Predicting Optimal Warfarin Dosagerian S. Finkelman, Brian F. Gage, Julie A. Johnson, Colleen M. Brensinger, Stephen E. Kimmel
inkelman and colleagues compared the accuracy of 5 dose prediction methods for predicting
he optimal dose of warfarin in a retrospective cohort study. Two of the methods use only
linical information (empiric 5 mg/day dosing and a formal clinical algorithm), 2 genetic
ables (the new warfarin label table and a table based on mean dose stratified by genotype),
nd 1 formal pharmacogenetic algorithm, using both clinical and genetic information. The
harmacogenetic algorithm was superior, with the predicted dose being within 20% of the
ctual dose in 52% of patients, compared with 37% to 44% for the other methods. Although
enetic tables may predict warfarin dose better than empiric dosing, formal pharmacogenetic
lgorithms are more accurate than all other dosing methods.(continued on page A-34)
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EROM AROUND THE WORLD619Parental History of MI is a Strong Predictor of Risklara K. Chow, Shofiqul Islam, Leonelo Bautista, Zvonko Rumboldt, Afzal Yusufali, Changchun Xie,
onia S. Anand, James C. Engert, Sumathy Rangarajan, Salim Yusuf
how and colleagues used data from 52 countries collected for the INTERHEART study to
etermine if the relationship between parental history (PH) of myocardial infarction (MI) and
I risk is independent of known cardiovascular risk factors or genetic variants. The odds
atio for MI associated with a PH of MI was 1.66 if one parent 50 years of age had an
I, with a stepwise increase to 3.26 if both parents had an MI and one was 50 years of
ge. The overall association of PH with MI was minimally attenuated after adjusting for
ypertension, diabetes, lipids, waist-to-hip ratio, tobacco use, alcohol use, physical activity,
ruit and vegetable intake, psychosocial factors, and genotype score. The strength of
ssociation was similar across all geographic and socioeconomic strata. PH of MI is an
mportant, consistent, and global determinant of risk that is not explained by variants in the
enes analyzed for this study.ditorial Comment: Themistocles L. Assimes, p. 628
